Technical Analysis for VVUS - VIVUS, Inc.

Grade Last Price % Change Price Change
grade D 4.64 0.22% 0.01
VVUS closed up 0.22 percent on Tuesday, March 19, 2019, on 10 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical VVUS trend table...

Date Alert Name Type % Chg
Mar 19 50 DMA Support Bullish 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 19 Bollinger Band Squeeze Range Contraction 0.00%
Mar 19 Doji - Bullish? Reversal 0.00%
Mar 18 MACD Bearish Centerline Cross Bearish 0.22%
Mar 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.22%
Mar 18 Bollinger Band Squeeze Range Contraction 0.22%
Mar 15 Bollinger Band Squeeze Range Contraction 0.87%
Mar 14 Bollinger Band Squeeze Range Contraction -2.32%
Mar 14 Narrow Range Bar Range Contraction -2.32%

Older signals for VVUS ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
VIVUS, Inc., a biopharmaceutical company, engages in developing and commercializing therapies to address unmet needs in obesity, sleep apnea, diabetes, and sexual health. The company offers Qsymia, a drug for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol; and STENDRA for the treatment of erectile dysfunction. It also completed Phase II clinical studies of Qsymia for the treatment of obstructive sleep apnea; and Qsymia for the treatment of type 2 diabetes. The company has an agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.
Medicine Chemistry Health Biopharmaceutical Diabetes Obesity Hypertension Diabetes Mellitus Psychiatric Diagnosis Obstructive Sleep Apnea Sleep Disorders Sleep Apnea Erectile Dysfunction Chronic Weight Management Female Sexual Dysfunction High Cholesterol Treatment Of Obesity
Is VVUS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.88
52 Week Low 2.15
Average Volume 164,397
200-Day Moving Average 5.0562
50-Day Moving Average 4.6078
20-Day Moving Average 4.808
10-Day Moving Average 4.695
Average True Range 0.2304
ADX 21.42
+DI 17.1298
-DI 17.4989
Chandelier Exit (Long, 3 ATRs ) 5.0888
Chandelier Exit (Short, 3 ATRs ) 5.0612
Upper Bollinger Band 5.1551
Lower Bollinger Band 4.4609
Percent B (%b) 0.26
BandWidth 14.438436
MACD Line -0.0101
MACD Signal Line 0.0409
MACD Histogram -0.051
Fundamentals Value
Market Cap 490.98 Million
Num Shares 106 Million
EPS 0.31
Price-to-Earnings (P/E) Ratio 14.97
Price-to-Sales 0.55
Price-to-Book 13.45
PEG Ratio -2.24
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.83
Resistance 3 (R3) 4.83 4.76 4.80
Resistance 2 (R2) 4.76 4.72 4.76 4.79
Resistance 1 (R1) 4.70 4.69 4.73 4.70 4.78
Pivot Point 4.64 4.64 4.65 4.64 4.64
Support 1 (S1) 4.58 4.59 4.61 4.58 4.50
Support 2 (S2) 4.51 4.56 4.51 4.49
Support 3 (S3) 4.45 4.51 4.48
Support 4 (S4) 4.45